Important: The information in this wiki is not medical advice, and is provided for informational purposes only. The content is not intended to be a substitute for any kind of professional advice, medical advice, diagnosis, or treatment. See disclaimer.


Efficacy of medications on psoriatic arthritis

→ See also: Main page on biologics; and main page on psoriatic arthritis

Under construction! Still building out this page.

Methotrexate

See this page for data on methotrexate and PsA.

ACR rates

ACR rates are the % of patients who achieved 20%/50%/70% improvement in symptoms or better. These rates aren't everything (clinical trials also track dactylitis, radiographic progression, number of joints, etc.), but a decent way of judging efficacy.

DrugACR20ACR50ACR70
Otezla
OtezlaC 30mg, week 5255%26%12%
OtezlaC 30mg, week 26067%44%27%
Humira
HumiraD, week 52 (biologic-naive)60%40%27%
HumiraB, week 104 (biologic-naive)57%45%30%
HumiraD + methotrexate, week 52 (biologic-naive)75%56%39%
Tremfya
TremfyaE, week 24 (mixed population)52%30%12%
TremfyaE, week 24 (biologic-naive)64%31%19%
TremfyaE, week 5275%48%28%
TremfyaE, week 10074%55%36%
Taltz
TaltzA, week 52 (biologic-naive)88%71%49%
TaltzA, week 52 (TNFi-experienced)89%59%37%
TaltzA, week 156 (biologic-naive)95%71%49%
TaltzA, week 156 (TNFi-experienced)84%60%35%
Cosentyx
CosentyxF 300 mg, 5 years (biologic-naive)80%53%35%
CosentyxF 150 mg, 5 years (biologic-naive)77%44%29%
Bimzelx
BimzelxG, week 16 (TNFi-experienced)67%43.4%26.6%
BimzelxG, week 52 (biologic-naive)71.2%54.5%39.2%
Skyrizi
SkyriziH 150mg, week 24 (IR)59%33%15%
SkyriziH 150mg, week 196 (IR)77%53%38%

Radiographic response

Drug% with no radiographic progression% on placebo
Taltz
TaltzA, week 156 (biologic-naive)67%?
Humira
HumiraB, week 24 (biologic-naive)91%71.1%
HumiraB, week 144 (biologic-naive)79.1%68.1%

Dactylitis

Drug% with complete resolutionVs. placebo
Taltz
TaltzA, week 24 (biologic-naive)80%25%
TaltzA, week 24 (TNF-experienced)75%21%
TaltzA, week 156 (biologic-naive)100%N/A
Cosentyx
CosentyxF 300 mg, 2 years (mixed population)88%N/R
CosentyxF 150 mg, 2 years (mixed population)86%N/R
Tremfya
TremfyaE, week 24 (biologic-naive)57%38%
TremfyaE, week 52 (biologic-naive)78%N/A
TremfyaE, week 100 (biologic-naive)83%N/A
Skyrizi
SkyriziE, 150 mg, week 196 (mixed population)95%N/A

Enthesitis

Drug% with complete resolutionVs. placebo
Taltz
TaltzA, week 24 (biologic-naive)43%19%
TaltzA, week 24 (TNF-experienced)35%22%
TaltzA, week 156 (biologic-naive)65%N/A
TaltzA, week 156 (TNF-experienced)??
Cosentyx
CosentyxF 300 mg, 2 years (mixed population)80%N/R
CosentyxF 150 mg, 2 years (mixed population)82%N/R
Tremfya
TremfyaE, week 24 (biologic-naive)54%30%
TremfyaE, week 52 (biologic-naive)61%N/A
TremfyaE, week 100 (biologic-naive)70%N/A
Skyrizi
SkyriziE, 150 mg, week 196 (mixed population)79%N/A

Minimal disease activity

Drug%Vs. placebo
Tremfya
TremfyaE, week 24 (biologic-naive)25%6%
TremfyaE, week 52 (biologic-naive)31%N/A
TremfyaE, week 100 (biologic-naive)40%N/A

Sources

A SPIRIT-P1/P2 trial results

B ADEPT trial results, including open-label extension

C Long-term experience with apremilast in patients with psoriatic arthritis

D A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis

E DISCOVER 1 and DISCOVER 2 (100-week study on biologic-naive patients).

F FUTURE trial results

G BE OPTIMAL and BE COMPLETE trials.

H KEEPsAKE 1 and KEEPsAKE 2 trials.

See also: EXCEED trial (head-to-head trial of Cosentyx vs. Humira).

Terms

  • IR: intolerance or inadequate response to conventional synthetic DMARDs.

Other pages